Stauprimide is known to prime Embryonic Stem Cells (ESC) by targeting the c-Myc-activating transcription factor NME2. Its mechanism of action is linked to the inhibition of the nuclear localization of NME2 leading to the downregulation of the transcription of the c-myc oncogene.
In a recent study, Bouvard C. et al. evidenced that Stauprimide’s mechanism of action could also be used to pharmacologically targetc-myc transcription in cancers. [Read more…]